Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer.

Serna G, Ruiz-Pace F, Cecchi F, Fasani R, Jimenez J, Thyparambil S, Landolfi S, Elez E, Vivancos A, Hembrough T, Tabernero J, Dienstmann R, Nuciforo P.

Sci Rep. 2019 Sep 19;9(1):13568. doi: 10.1038/s41598-019-49867-7.

2.

Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.

Dienstmann R, Villacampa G, Sveen A, Mason MJ, Niedzwiecki D, Nesbakken A, Moreno V, Warren RS, Lothe RA, Guinney J.

Ann Oncol. 2019 Aug 27. pii: mdz287. doi: 10.1093/annonc/mdz287. [Epub ahead of print]

PMID:
31504112
3.

Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer.

Rodriguez-Freixinos V, Ruiz-Pace F, Fariñas-Madrid L, Garrido-Castro AC, Villacampa G, Nuciforo P, Vivancos A, Dienstmann R, Oaknin A.

ESMO Open. 2019 Mar 8;4(2):e000444. doi: 10.1136/esmoopen-2018-000444. eCollection 2019.

4.

New clinical trial designs in the era of precision medicine.

Garralda E, Dienstmann R, Piris-Giménez A, Braña I, Rodon J, Tabernero J.

Mol Oncol. 2019 Mar;13(3):549-557. doi: 10.1002/1878-0261.12465. Epub 2019 Feb 22. Review.

5.

Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.

Rodriguez-Freixinos V, Fariñas-Madrid L, Gil-Martin M, Barretina-Ginesta P, Romeo M, Villacampa G, Pardo B, Ahmed H, Recalde S, Piulats JM, Gómez-Plaza MC, Gil-Moreno A, Sala E, Martínez-Román S, Ponce J, Meléndez C, Carballas E, Dienstmann R, Oaknin A.

Gynecol Oncol. 2019 Feb;152(2):270-277. doi: 10.1016/j.ygyno.2018.11.036. Epub 2018 Dec 12.

PMID:
30551885
6.

Should next-generation sequencing testing be routinely used in metastatic colorectal cancer?

Dienstmann R, Ciner A, Hochster HS.

Lancet Oncol. 2018 Nov;19(11):1434-1435. doi: 10.1016/S1470-2045(18)30776-9. Epub 2018 Nov 1. No abstract available.

PMID:
30507475
7.

Precision oncology: separating the wheat from the chaff.

Remon J, Dienstmann R.

ESMO Open. 2018 Oct 30;3(6):e000446. doi: 10.1136/esmoopen-2018-000446. eCollection 2018.

8.

Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2.

Chang K, Willis JA, Reumers J, Taggart MW, San Lucas FA, Thirumurthi S, Kanth P, Delker DA, Hagedorn CH, Lynch PM, Ellis LM, Hawk ET, Scheet PA, Kopetz S, Arts J, Guinney J, Dienstmann R, Vilar E.

Ann Oncol. 2018 Oct 1;29(10):2061-2067. doi: 10.1093/annonc/mdy337.

9.

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.

Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, Gutiérrez-Enríquez S, Ducy M, Ibrahim YH, Gris-Oliver A, Pellegrino B, Bruna A, Guzmán M, Rodríguez O, Grueso J, Bonache S, Moles-Fernández A, Villacampa G, Viaplana C, Gómez P, Vidal M, Peg V, Serres-Créixams X, Dellaire G, Simard J, Nuciforo P, Rubio IT, Dienstmann R, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Déas O, Jonkers J, Masson JY, Cairo S, Judde JG, O'Connor MJ, Díez O, Balmaña J, Serra V.

EMBO Mol Med. 2018 Dec;10(12). pii: e9172. doi: 10.15252/emmm.201809172.

10.

Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer.

Dienstmann R, Salazar R, Tabernero J.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:231-238. doi: 10.1200/EDBK_200929. Review.

PMID:
30231342
11.

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL, Tortora G, Douillard JY, Van Allen EM, Schultz N, Swanton C, André F, Pusztai L.

Ann Oncol. 2018 Sep 1;29(9):1895-1902. doi: 10.1093/annonc/mdy263.

12.

Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy.

Allen WL, Dunne PD, McDade S, Scanlon E, Loughrey M, Coleman H, McCann C, McLaughlin K, Nemeth Z, Syed N, Jithesh P, Arthur K, Wilson R, Coyle V, McArt D, Murray GI, Samuel L, Nuciforo P, Jimenez J, Argiles G, Dienstmann R, Tabernero J, Messerini L, Nobili S, Mini E, Sheahan K, Ryan E, Johnston PG, Van Schaeybroeck S, Lawler M, Longley DB.

JCO Precis Oncol. 2018 Jun 13;2018. doi: 10.1200/PO.17.00241.

13.

TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence.

Puig I, Tenbaum SP, Chicote I, Arqués O, Martínez-Quintanilla J, Cuesta-Borrás E, Ramírez L, Gonzalo P, Soto A, Aguilar S, Eguizabal C, Caratù G, Prat A, Argilés G, Landolfi S, Casanovas O, Serra V, Villanueva A, Arroyo AG, Terracciano L, Nuciforo P, Seoane J, Recio JA, Vivancos A, Dienstmann R, Tabernero J, Palmer HG.

J Clin Invest. 2018 Aug 31;128(9):3887-3905. doi: 10.1172/JCI96393. Epub 2018 Aug 6.

14.

A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations.

Tamborero D, Rubio-Perez C, Muiños F, Sabarinathan R, Piulats JM, Muntasell A, Dienstmann R, Lopez-Bigas N, Gonzalez-Perez A.

Clin Cancer Res. 2018 Aug 1;24(15):3717-3728. doi: 10.1158/1078-0432.CCR-17-3509. Epub 2018 Apr 17.

15.

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations.

Tamborero D, Rubio-Perez C, Deu-Pons J, Schroeder MP, Vivancos A, Rovira A, Tusquets I, Albanell J, Rodon J, Tabernero J, de Torres C, Dienstmann R, Gonzalez-Perez A, Lopez-Bigas N.

Genome Med. 2018 Mar 28;10(1):25. doi: 10.1186/s13073-018-0531-8.

16.

CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.

Smeby J, Sveen A, Merok MA, Danielsen SA, Eilertsen IA, Guren MG, Dienstmann R, Nesbakken A, Lothe RA.

Ann Oncol. 2018 May 1;29(5):1227-1234. doi: 10.1093/annonc/mdy085.

17.

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.

Montagut C, Argilés G, Ciardiello F, Poulsen TT, Dienstmann R, Kragh M, Kopetz S, Lindsted T, Ding C, Vidal J, Clausell-Tormos J, Siravegna G, Sánchez-Martín FJ, Koefoed K, Pedersen MW, Grandal MM, Dvorkin M, Wyrwicz L, Rovira A, Cubillo A, Salazar R, Desseigne F, Nadal C, Albanell J, Zagonel V, Siena S, Fumi G, Rospo G, Nadler P, Horak ID, Bardelli A, Tabernero J.

JAMA Oncol. 2018 Apr 12;4(4):e175245. doi: 10.1001/jamaoncol.2017.5245. Epub 2018 Apr 12. Erratum in: JAMA Oncol. 2019 May 1;5(5):745.

18.

Tumor Side as Model of Integrative Molecular Classification of Colorectal Cancer.

Dienstmann R.

Clin Cancer Res. 2018 Mar 1;24(5):989-990. doi: 10.1158/1078-0432.CCR-17-3477. Epub 2017 Dec 21.

19.

Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies.

Sveen A, Bruun J, Eide PW, Eilertsen IA, Ramirez L, Murumägi A, Arjama M, Danielsen SA, Kryeziu K, Elez E, Tabernero J, Guinney J, Palmer HG, Nesbakken A, Kallioniemi O, Dienstmann R, Lothe RA.

Clin Cancer Res. 2018 Feb 15;24(4):794-806. doi: 10.1158/1078-0432.CCR-17-1234. Epub 2017 Dec 14.

20.

Reply to the letter to the editor 'Including lynch syndrome in personalized prognostication and follow-up of stage II and III colon cancer' by Sciallero et al.

Dienstmann R, Guinney J.

Ann Oncol. 2017 Nov 1;28(11):2889-2890. doi: 10.1093/annonc/mdx415. No abstract available.

PMID:
29045507
21.

Genomic Determinants of Protein Abundance Variation in Colorectal Cancer Cells.

Roumeliotis TI, Williams SP, Gonçalves E, Alsinet C, Del Castillo Velasco-Herrera M, Aben N, Ghavidel FZ, Michaut M, Schubert M, Price S, Wright JC, Yu L, Yang M, Dienstmann R, Guinney J, Beltrao P, Brazma A, Pardo M, Stegle O, Adams DJ, Wessels L, Saez-Rodriguez J, McDermott U, Choudhary JS.

Cell Rep. 2017 Aug 29;20(9):2201-2214. doi: 10.1016/j.celrep.2017.08.010.

22.

Cancer: A precision approach to tumour treatment.

Dienstmann R, Tabernero J.

Nature. 2017 Aug 3;548(7665):40-41. doi: 10.1038/nature23101. Epub 2017 Jul 19. No abstract available.

PMID:
28723897
23.

Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights.

Dienstmann R, Elez E, Argiles G, Matos I, Sanz-Garcia E, Ortiz C, Macarulla T, Capdevila J, Alsina M, Sauri T, Verdaguer H, Vilaro M, Ruiz-Pace F, Viaplana C, Garcia A, Landolfi S, Palmer HG, Nuciforo P, Rodon J, Vivancos A, Tabernero J.

Mol Oncol. 2017 Sep;11(9):1263-1272. doi: 10.1002/1878-0261.12099. Epub 2017 Jul 20.

24.

Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology.

Garralda E, Dienstmann R, Tabernero J.

Am Soc Clin Oncol Educ Book. 2017;37:210-215. doi: 10.14694/EDBK_180460. Review.

PMID:
28561730
25.

Personalizing Adjuvant Therapy for Stage II/III Colorectal Cancer.

McCleary NJ, Benson AB 3rd, Dienstmann R.

Am Soc Clin Oncol Educ Book. 2017;37:232-245. doi: 10.14694/EDBK_175660. Review.

PMID:
28561714
26.

Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.

Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, Danielsen SA, Sveen A, Buchanan DD, Clendenning M, Rosty C, Bot B, Alberts SR, Milburn Jessup J, Lothe RA, Delorenzi M, Newcomb PA, Sargent D, Guinney J.

Ann Oncol. 2017 May 1;28(5):1023-1031. doi: 10.1093/annonc/mdx052.

27.

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.

Grasselli J, Elez E, Caratù G, Matito J, Santos C, Macarulla T, Vidal J, Garcia M, Viéitez JM, Paéz D, Falcó E, Lopez Lopez C, Aranda E, Jones F, Sikri V, Nuciforo P, Fasani R, Tabernero J, Montagut C, Azuara D, Dienstmann R, Salazar R, Vivancos A.

Ann Oncol. 2017 Jun 1;28(6):1294-1301. doi: 10.1093/annonc/mdx112.

28.

Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer.

Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J.

Nat Rev Cancer. 2017 Mar 23;17(4):268. doi: 10.1038/nrc.2017.24. No abstract available.

PMID:
28332502
29.

CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer.

Griffith M, Spies NC, Krysiak K, McMichael JF, Coffman AC, Danos AM, Ainscough BJ, Ramirez CA, Rieke DT, Kujan L, Barnell EK, Wagner AH, Skidmore ZL, Wollam A, Liu CJ, Jones MR, Bilski RL, Lesurf R, Feng YY, Shah NM, Bonakdar M, Trani L, Matlock M, Ramu A, Campbell KM, Spies GC, Graubert AP, Gangavarapu K, Eldred JM, Larson DE, Walker JR, Good BM, Wu C, Su AI, Dienstmann R, Margolin AA, Tamborero D, Lopez-Bigas N, Jones SJ, Bose R, Spencer DH, Wartman LD, Wilson RK, Mardis ER, Griffith OL.

Nat Genet. 2017 Jan 31;49(2):170-174. doi: 10.1038/ng.3774. No abstract available.

30.

Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer.

Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J.

Nat Rev Cancer. 2017 Feb;17(2):79-92. doi: 10.1038/nrc.2016.126. Epub 2017 Jan 4. Review. Erratum in: Nat Rev Cancer. 2017 Mar 23;17 (4):268.

PMID:
28050011
31.

Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment.

Dienstmann R, Tabernero J.

Cancer J. 2016 May-Jun;22(3):149-55. doi: 10.1097/PPO.0000000000000191. Review.

PMID:
27341591
32.

Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies.

Azuara D, Santos C, Lopez-Doriga A, Grasselli J, Nadal M, Sanjuan X, Marin F, Vidal J, Montal R, Moreno V, Bellosillo B, Argiles G, Elez E, Dienstmann R, Montagut C, Tabernero J, Capellá G, Salazar R.

Mol Cancer Ther. 2016 May;15(5):1106-12. doi: 10.1158/1535-7163.MCT-15-0820. Epub 2016 Apr 1.

33.

The consensus molecular subtypes of colorectal cancer.

Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S.

Nat Med. 2015 Nov;21(11):1350-6. doi: 10.1038/nm.3967. Epub 2015 Oct 12.

34.

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.

Tabernero J, Bahleda R, Dienstmann R, Infante JR, Mita A, Italiano A, Calvo E, Moreno V, Adamo B, Gazzah A, Zhong B, Platero SJ, Smit JW, Stuyckens K, Chatterjee-Kishore M, Rodon J, Peddareddigari V, Luo FR, Soria JC.

J Clin Oncol. 2015 Oct 20;33(30):3401-8. doi: 10.1200/JCO.2014.60.7341. Epub 2015 Aug 31.

PMID:
26324363
35.

First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors.

Dienstmann R, Lassen U, Cebon J, Desai J, Brown MP, Evers S, Su F, Zhang W, Boisserie F, Lestini B, Schostack K, Meresse V, Tabernero J.

Target Oncol. 2016 Apr;11(2):149-56. doi: 10.1007/s11523-015-0381-x.

PMID:
26310975
36.

MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.

García-García C, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodríguez O, Grueso J, Antón P, Guzmán M, Aura C, Nuciforo P, Jessen K, Argilés G, Dienstmann R, Bertotti A, Trusolino L, Matito J, Vivancos A, Chicote I, Palmer HG, Tabernero J, Scaltriti M, Baselga J, Serra V.

Clin Cancer Res. 2015 Dec 15;21(24):5499-5510. doi: 10.1158/1078-0432.CCR-14-3091. Epub 2015 Aug 13. Erratum in: Clin Cancer Res. 2016 Aug 1;22(15):3982.

37.

Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.

Arqués O, Chicote I, Puig I, Tenbaum SP, Argilés G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG.

Clin Cancer Res. 2016 Feb 1;22(3):644-56. doi: 10.1158/1078-0432.CCR-14-3081. Epub 2015 Jul 29.

38.

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.

Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith W, Blumenschein GR Jr, Tabernero J, Roda D, Calles A, Jimeno A, Wang X, Bohórquez SS, Leddy C, Littman C, Kapp AV, Shames DS, Penuel E, Amler LC, Pirzkall A, Baselga J.

Clin Cancer Res. 2015 Jun 1;21(11):2462-70. doi: 10.1158/1078-0432.CCR-14-2412.

39.

Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer.

Dienstmann R, Salazar R, Tabernero J.

Am Soc Clin Oncol Educ Book. 2015:e149-56. doi: 10.14694/EdBook_AM.2015.35.e149. Review.

40.

Heterogeneity of driver genes and therapeutic implications in colorectal cancer.

Dienstmann R, Cervantes A.

Ann Oncol. 2015 Aug;26(8):1523-5. doi: 10.1093/annonc/mdv229. Epub 2015 May 12. No abstract available.

PMID:
25969371
41.

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.

Dienstmann R, Patnaik A, Garcia-Carbonero R, Cervantes A, Benavent M, Roselló S, Tops BB, van der Post RS, Argilés G, Skartved NJ, Hansen UH, Hald R, Pedersen MW, Kragh M, Horak ID, Braun S, Van Cutsem E, Tolcher AW, Tabernero J.

Cancer Discov. 2015 Jun;5(6):598-609. doi: 10.1158/2159-8290.CD-14-1432. Epub 2015 May 11.

42.

Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients.

Dienstmann R, Salazar R, Tabernero J.

J Clin Oncol. 2015 Jun 1;33(16):1787-96. doi: 10.1200/JCO.2014.60.0213. Epub 2015 Apr 27. Review.

PMID:
25918287
43.

A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3.

Mau-Sørensen M, Dittrich C, Dienstmann R, Lassen U, Büchler W, Martinius H, Tabernero J.

Cancer Chemother Pharmacol. 2015 May;75(5):1065-73. doi: 10.1007/s00280-015-2728-5. Epub 2015 Mar 27.

PMID:
25814216
44.

Genomic testing in colorectal cancer: how much is enough?

Dienstmann R, Salazar R, Tabernero J.

Oncology (Williston Park). 2015 Mar;29(3):186-8. No abstract available.

45.

Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors.

Dienstmann R, Jang IS, Bot B, Friend S, Guinney J.

Cancer Discov. 2015 Feb;5(2):118-23. doi: 10.1158/2159-8290.CD-14-1118.

46.
47.

Intrinsic cancer subtypes--next steps into personalized medicine.

Santos C, Sanz-Pamplona R, Nadal E, Grasselli J, Pernas S, Dienstmann R, Moreno V, Tabernero J, Salazar R.

Cell Oncol (Dordr). 2015 Feb;38(1):3-16. doi: 10.1007/s13402-014-0203-7. Epub 2015 Jan 14. Review.

PMID:
25586691
48.

Social interactomes for enabling research communities.

Guinney J, Dienstmann R, Ferté C, Friend S, McCormick F.

Cancer Discov. 2014 Nov;4(11):1265-8. doi: 10.1158/2159-8290.CD-14-0774.

49.

Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.

Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, Bot BM, Tejpar S, Delorenzi M, Goldberg RM, Mahoney M, Sargent DJ, Alberts SR.

Gastroenterology. 2015 Jan;148(1):88-99. doi: 10.1053/j.gastro.2014.09.041. Epub 2014 Oct 8.

50.

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.

Soria JC, DeBraud F, Bahleda R, Adamo B, Andre F, Dienstmann R, Delmonte A, Cereda R, Isaacson J, Litten J, Allen A, Dubois F, Saba C, Robert R, D'Incalci M, Zucchetti M, Camboni MG, Tabernero J.

Ann Oncol. 2014 Nov;25(11):2244-51. doi: 10.1093/annonc/mdu390. Epub 2014 Sep 5. Erratum in: Ann Oncol. 2015 Feb;26(2):445. Dientsmann, R [corrected to Dienstmann, R].

PMID:
25193991

Supplemental Content

Loading ...
Support Center